Physician profile
True B Hooper
NPI 1427391903
$1,333.25
in general payments reported to CMS, 2019-2025
19 companies · $52.83 in 2025
The $52.83 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.12 · 2020: $88.41 · 2021: $81.54 · 2022: $357 · 2023: $315 · 2024: $360 · 2025: $52.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $312.99 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $278.85 | 2019-2023 | Pediarix, Bexsero |
| Supernus Pharmaceuticals, INC. | $112.56 | 2023-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $66.69 | 2021-2022 | |
| Pfizer INC. | $63.92 | 2021-2024 | |
| Ironshore Pharmaceuticals INC. | $58.81 | 2022-2024 | Jornay Pm |
| Adlon Therapeutics L.P. | $54.99 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $53.69 | 2022-2024 | Vaxelis, Vaxneuvance, Gardasil |
| Sanofi Pasteur INC. | $46.03 | 2023-2024 | |
| Sobi, INC | $42.72 | 2023 | |
| Tris Pharma INC | $39.41 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $36.30 | 2022 | |
| Biomarin Pharmaceutical INC. | $34.06 | 2024 | Voxzogo 1.2mg |
| Neos Therapeutics, LP | $33.53 | 2020-2024 | Adzenys Xr-Odt |
| Astrazeneca Pharmaceuticals LP | $30.34 | 2024 | Flumist Quadrivalent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofire Diagnostics, LLC | $22.07 | 2020 | |
| Collegium Pharmaceutical, INC. | $17.73 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $14.71 | 2025 | Daybue |
| Seqirus USA INC | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw True Hooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.